目的:检测parafibromin蛋白在人颌骨骨肉瘤(osteosarcoma of the jaws,JOS)中的表达情况,探讨其在JOS的发生、发展中的作用。方法:采用免疫组织化学的方法检测parafibromin蛋白在47例JOS和11例颌骨骨化纤维瘤(ossifying fibroma of the jaws,JOF)中的表达情况。结果:JOS中,parafibromin高表达、中等表达、低表达患者分别占48.9%(23/47)、40.4%(19/47)和10.7%(5/47);JOF中,三者所占的百分率分别为90.9%(10/11)、9.1%(1/11)和0.0%(0),与JOS相比,差异有统计学意义(U=147.5,P=0.012);parafibromin在高分化型JOS中的表达水平高于传统型JOS(U=71.0,P=0.021);parafibromin的表达情况与临床病理参数间无相关性(P〉0.05)。结论:parafibromin蛋白在JOS中表达下调,这种表达的减少可能与JOS的分化和恶性程度有关。
Objective: To investigate the expression of parafibromin in osteosarcoma of the jaws(JOS) and to explore its effects on tumorigenesis and progression.Methods: The expression of parafibromin was studied in 47 JOS and 11 ossifying fibroma of the jaws(JOF) by immunohistochemically staining.Results: In JOS,the high,medium and low levels of parafibromin expression were detected in 48.9%(23/47),40.4%(19/47),and 10.7%(5/47) of the cases,respectively;correspondingly,the different expressions were seen in 90.9%(10/11),9.1%(1/11),and 0.0%(0) JOF cases respectively.The difference between JOS and JOF groups was significantly different(U=147.5,P=0.012).In highly differentiated JOS,the expression of parafibromin was significantly higher than that in the conventional JOS(U=71.0,P=0.021) but there were no statistically correlations between the expression of para-fibromin and clinical-pathological parameters of JOS(P0.05).Conclusion: It is possible that the down-regulation of parafibromin may be associated with the differentiation and malignant degree of JOS.